Literature DB >> 20702843

Parkinson's disease: mitochondrial molecular pathology, inflammation, statins, and therapeutic neuroprotective nutrition.

Richard Kones1.   

Abstract

Pathological hallmarks of Parkinson's disease are destruction of dopaminergic neurons in the basal ganglia, especially the substantia nigra, and the presence of Lewy bodies within nerve cells. Environmental toxins are associated with the disease and, in a minority of cases, genetic factors have been identified. Inflammation-with activation of phagocytic microglia, release of cytokines, invasion by T cells, and complement activation-plays a role in damaging these neurons. Excessive production of reactive oxygen species, mitochondrial dysfunction leading to apoptosis, accumulation and oligomerization of the protein alpha-synuclein, and defective protein disposal by the ubiquitin proteasome system are involved in the complex web of events mediating nigral cell demise. Two agents of current interest, coenzyme Q10 and creatine, may be disease modifying, and large studies are in progress. Related mechanisms of other substances, including omega-3 fatty acids and vitamin D, are included in this review. The association with serum cholesterol levels and the effects of statin drugs are uncertain but important.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20702843     DOI: 10.1177/0884533610373932

Source DB:  PubMed          Journal:  Nutr Clin Pract        ISSN: 0884-5336            Impact factor:   3.080


  13 in total

1.  Enhanced mitochondrial inhibition by 3,4-dihydroxyphenyl-acetaldehyde (DOPAL)-oligomerized α-synuclein.

Authors:  Theodore A Sarafian; Amneh Yacoub; Anastasia Kunz; Burkan Aranki; Grigor Serobyan; Whitaker Cohn; Julian P Whitelegge; Joseph B Watson
Journal:  J Neurosci Res       Date:  2019-08-16       Impact factor: 4.164

2.  Sulfuretin protects hepatic cells through regulation of ROS levels and autophagic flux.

Authors:  Yu-Ting Lu; Yu-Feng Xiao; Yu-Feng Li; Jia Li; Fa-Jun Nan; Jing-Ya Li
Journal:  Acta Pharmacol Sin       Date:  2018-12-18       Impact factor: 6.150

Review 3.  Assessing mitochondrial dysfunction in cells.

Authors:  Martin D Brand; David G Nicholls
Journal:  Biochem J       Date:  2011-04-15       Impact factor: 3.857

Review 4.  Stem Cell Transplantation and Physical Exercise in Parkinson's Disease, a Literature Review of Human and Animal Studies.

Authors:  Jaison Daniel Cucarián Hurtado; Jenny Paola Berrío Sánchez; Ramiro Barcos Nunes; Alcyr Alves de Oliveira
Journal:  Stem Cell Rev Rep       Date:  2018-04       Impact factor: 5.739

Review 5.  Convergent Molecular Pathways in Type 2 Diabetes Mellitus and Parkinson's Disease: Insights into Mechanisms and Pathological Consequences.

Authors:  Sandeep Xxxx; Mir Hilal Ahmad; Linchi Rani; Amal Chandra Mondal
Journal:  Mol Neurobiol       Date:  2022-05-16       Impact factor: 5.590

6.  Mitochondrial therapeutics in Alzheimer's disease and Parkinson's disease.

Authors:  Jake G Hoekstra; Kathleen S Montine; Jing Zhang; Thomas J Montine
Journal:  Alzheimers Res Ther       Date:  2011-06-29       Impact factor: 6.982

7.  Cell viability and dopamine secretion of 6-hydroxydopamine-treated PC12 cells co-cultured with bone marrow-derived mesenchymal stem cells.

Authors:  Yue Tang; Yongchun Cui; Fuliang Luo; Xiaopeng Liu; Xiaojuan Wang; Aili Wu; Junwei Zhao; Zhong Tian; Like Wu
Journal:  Neural Regen Res       Date:  2012-05-15       Impact factor: 5.135

8.  High expression of the HMGB1-TLR4 axis and its downstream signaling factors in patients with Parkinson's disease and the relationship of pathological staging.

Authors:  Yi Yang; Chenyang Han; Li Guo; Qiaobin Guan
Journal:  Brain Behav       Date:  2018-03-25       Impact factor: 2.708

9.  Melatonin regulates mitochondrial dynamics and alleviates neuron damage in prion diseases.

Authors:  Xixi Zhang; Deming Zhao; Wei Wu; Syed Zahid Ali Shah; Mengyu Lai; Dongming Yang; Jie Li; Zhiling Guan; Wen Li; Hongli Gao; Huafen Zhao; Xiangmei Zhou; Lifeng Yang
Journal:  Aging (Albany NY)       Date:  2020-06-10       Impact factor: 5.682

10.  Proteasome-targeted nanobodies alleviate pathology and functional decline in an α-synuclein-based Parkinson's disease model.

Authors:  Diptaman Chatterjee; Mansi Bhatt; David Butler; Erwin De Genst; Christopher M Dobson; Anne Messer; Jeffrey H Kordower
Journal:  NPJ Parkinsons Dis       Date:  2018-08-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.